GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Mantle Cell Lymphoma
Related studies linked through entity extraction aliases.
Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
- Status
- RECRUITING
- Phase
- PHASE3
Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
- Status
- RECRUITING
- Phase
- PHASE1
Italian Observational Study on CAR-T Therapy for Lymphoma
- Status
- RECRUITING
- Phase
- N/A
Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma.
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas
- Status
- RECRUITING
- Phase
- PHASE2
Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients
- Status
- RECRUITING
- Phase
- PHASE2
A Single-arm, Single-center, Open-label Phase II Study of Zanubrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle CellLymphoma Patients
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Preliminary Assessment of [18F]BL40 in PET/CT Scans
- Status
- NOT_YET_RECRUITING
- Phase
- N/A
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
- Status
- RECRUITING
- Phase
- PHASE1
A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study
- Status
- RECRUITING
- Phase
- N/A
TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Patient Perspectives in Mantle Cell Lymphoma Clinical Research
- Status
- NOT_YET_RECRUITING
- Phase
- N/A